© 2005 Oxford University Press
BRIEF COMMUNICATION |
High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dubé–Associated Renal Tumors
Affiliations of authors: Urologic Oncology Branch (CDV, YY, CPP, CATC, MMW, WML), and Laboratory of Pathology (CATC, MJM), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Basic Research Program, SAIC–Frederick, Inc. (LSS), and Laboratory of Immunobiology, National Cancer Institute, Frederick, MD (MLN, BZ)
Correspondence to: Cathy D. Vocke, PhD, Urologic Oncology Branch, Bldg. 10, CRC, Rm. 1W-5888, National Cancer Institute, Bethesda, MD 20892 (e-mail: vockec{at}mail.nih.gov).
The Birt-Hogg-Dubé (BHD) syndrome is an inherited genodermatosis characterized by a predisposition to hamartomatous skin lesions, pulmonary cysts, and renal carcinoma. Seventy-seven renal tumors from 12 patients with germline BHD mutations were examined by DNA sequencing to identify somatic mutations in the second copy of BHD. Sequence alterations were detected in the majority of renal tumors (41 of 77, 53%), with loss of heterozygosity at the BHD locus in a minority of additional tumors (14 of 77, 17%). The somatic mutations were distributed across the entire gene, and the majority resulted in frameshifts that are predicted to truncate the BHD protein. These results support a role for BHD as a tumor suppressor gene that predisposes to the development of renal tumors when both copies are inactivated.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J R Toro, M-H Wei, G M Glenn, M Weinreich, O Toure, C Vocke, M Turner, P Choyke, M J Merino, P A Pinto, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports J. Med. Genet., June 1, 2008; 45(6): 321 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Mayr, D. Meierhofer, F. Zimmermann, R. Feichtinger, C. Kogler, M. Ratschek, N. Schmeller, W. Sperl, and B. Kofler Loss of Complex I due to Mitochondrial DNA Mutations in Renal Oncocytoma Clin. Cancer Res., April 15, 2008; 14(8): 2270 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Baba, M. Furihata, S.-B. Hong, L. Tessarollo, D. C. Haines, E. Southon, V. Patel, P. Igarashi, W. G. Alvord, R. Leighty, et al. Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys J Natl Cancer Inst, January 16, 2008; 100(2): 140 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gunji, T. Akiyoshi, T. Sato, M. Kurihara, S. Tominaga, K. Takahashi, and K. Seyama Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax J. Med. Genet., September 1, 2007; 44(9): 588 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Slegtenhorst, D. Khabibullin, T. R. Hartman, E. Nicolas, W. D. Kruger, and E. P. Henske The Birt-Hogg-Dube and Tuberous Sclerosis Complex Homologs Have Opposing Roles in Amino Acid Homeostasis in Schizosaccharomyces pombe J. Biol. Chem., August 24, 2007; 282(34): 24583 - 24590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iliopoulos Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Baba, S.-B. Hong, N. Sharma, M. B. Warren, M. L. Nickerson, A. Iwamatsu, D. Esposito, W. K. Gillette, R. F. Hopkins III, J. L. Hartley, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling PNAS, October 17, 2006; 103(42): 15552 - 15557. [Abstract] [Full Text] [PDF]
|
|